MONTEGGIO – Microsize, a U.S.-based contract drug manufacturer, said on Monday it has agreed to buy Micro-Macinazione (Mic Mac), a micronization facility in Monteggio, Switzerland, from Lonza Group AG, in a move to build a transatlantic particle engineering platform.
The deal, Microsize’s second acquisition from the Swiss life sciences giant, is part of a strategy to gain scale and specialization in a market that values technical expertise and reliable execution. Swiss equipment firm Schedio Group is co-investing in the transaction to localize and strengthen the operational base in Europe.
Financial terms of the deal were not disclosed.
The acquisition of Mic Mac, which has over 30 years of experience providing jet milling services to the pharmaceutical industry, will give Microsize a strategic European foothold. The facility brings GMP-compliant capabilities for both clinical and commercial supply, a skilled workforce, and a strong regulatory history.
“The acquisition agreement represents a critical step in building Microsize into a global leader in particle engineering,” said TJ Higley, CEO of Microsize. “It gives our customers seamless access to high-quality services on both sides of the Atlantic.”
The transaction follows Microsize’s 2022 purchase of Lonza’s particle size reduction site in Quakertown, Pennsylvania. Jan Vertommen, Vice President of Commercial Development at Lonza Advanced Synthesis, said the companies anticipate a smooth transition for Mic Mac’s customers.
Microsize and Schedio plan to jointly invest in the Swiss site to enhance its capabilities and accelerate modernization. The partnership aims to create an integrated network that combines Microsize’s contract development and manufacturing organization (CDMO) expertise with Schedio’s process equipment and containment technologies.
“This is a deliberate strategy to build scale and specialization in a market that rewards technical depth, customer trust, and execution,” said Derek Hennecke, Chairman of Microsize.
The transaction is expected to close during the first quarter of 2026, subject to customary closing conditions.